PMID- 31113794 OWN - NLM STAT- MEDLINE DCOM- 20200331 LR - 20200331 IS - 1468-2060 (Electronic) IS - 0003-4967 (Print) IS - 0003-4967 (Linking) VI - 78 IP - 9 DP - 2019 Sep TI - The contribution of joint and skin improvements to the health-related quality of life of patients with psoriatic arthritis: a post hoc analysis of two randomised controlled studies. PG - 1215-1219 LID - 10.1136/annrheumdis-2018-215003 [doi] AB - OBJECTIVE: Determine the contribution of joint and skin improvements to health-related quality of life (HRQoL) in patients with psoriatic arthritis (PsA). METHODS: SPIRIT-P1 and SPIRIT-P2 are phase 3 trials investigating ixekizumab, an interleukin-17A antagonist, in the treatment of patients with active PsA. Patients were randomised to ixekizumab or placebo. Outcomes included the Disease Activity Index for Psoriatic Arthritis (DAPSA), the Psoriasis Area and Severity Index (PASI), the European Quality of Life-Five Dimensions (EQ-5D) Visual Analogue Score (VAS), the 36-Item Short-Form Health Survey (SF-36) and the Work Productivity and Activity Impairment (WPAI) Questionnaire. The contribution of joint and skin improvements to HRQoL was modelled using a smoothing spline method and depicted with response surface graphics. RESULTS: In this integrated analysis, 402 patients with PsA had baseline psoriasis of >/=3% of body surface area. We applied response surface modelling to this patient data set to investigate the relationship between DAPSA, PASI and HRQoL improvements at week 24. The greatest improvement in EQ-5D VAS was associated with the largest per cent improvements in both DAPSA and PASI together, rather than DAPSA or PASI alone. Similar observations were made in domains of SF-36 and WPAI. CONCLUSION: Optimal improvements in patients' HRQoL were dependent on successful treatment of both joint and skin symptoms. CI - (c) Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. FAU - Kavanaugh, Arthur AU - Kavanaugh A AD - Department of Medicine, School of Medicine, University of California, San Diego, La Jolla, California, USA akavanaugh@ucsd.edu. FAU - Gottlieb, Alice AU - Gottlieb A AD - Department of Dermatology, Icahn School of Medicine at Mt. Sinai, New York, New York, USA. FAU - Morita, Akimichi AU - Morita A AD - Department of Geriatric and Environmental Dermatology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan. FAU - Merola, Joseph F AU - Merola JF AD - Department of Medicine, Division of Rheumatology, and Department of Dermatology, Harvard Medical School, Boston, Massachusetts, USA. AD - Department of Medicine, Division of Rheumatology, and Department of Dermatology, Brigham and Women's Hospital, Boston, Massachusetts, USA. FAU - Lin, Chen-Yen AU - Lin CY AD - Lilly Research Labs, Eli Lilly and Company, Indianapolis, Indiana, USA. FAU - Birt, Julie AU - Birt J AD - Lilly Research Labs, Eli Lilly and Company, Indianapolis, Indiana, USA. FAU - Shuler, Catherine L AU - Shuler CL AD - Lilly Research Labs, Eli Lilly and Company, Indianapolis, Indiana, USA. FAU - Hufford, Matthew M AU - Hufford MM AD - Lilly Research Labs, Eli Lilly and Company, Indianapolis, Indiana, USA. FAU - Thaci, Diamant AU - Thaci D AD - Comprehensive Center of Inflammation Medicine, University Hospital Schleswig-Holstein Campus, Luebeck, Germany. LA - eng PT - Clinical Trial, Phase III PT - Journal Article PT - Randomized Controlled Trial PT - Research Support, Non-U.S. Gov't DEP - 20190521 PL - England TA - Ann Rheum Dis JT - Annals of the rheumatic diseases JID - 0372355 RN - 0 (Antibodies, Monoclonal, Humanized) RN - 0 (Dermatologic Agents) RN - BTY153760O (ixekizumab) SB - IM MH - Antibodies, Monoclonal, Humanized/*administration & dosage MH - Arthritis, Psoriatic/diagnosis/*drug therapy/psychology MH - Dermatologic Agents/administration & dosage MH - Disease Progression MH - Dose-Response Relationship, Drug MH - Double-Blind Method MH - Female MH - Follow-Up Studies MH - Humans MH - Joints/*physiopathology MH - Male MH - Middle Aged MH - *Quality of Life MH - Range of Motion, Articular/*physiology MH - Severity of Illness Index MH - Skin/*pathology MH - Surveys and Questionnaires PMC - PMC6788877 OTO - NOTNLM OT - health-related quality of life OT - psoriasis OT - psoriatic arthritis OT - treatment COIS- Competing interests: AK has been a consultant for Eli Lilly and Company. AG has received consulting or advisory board honoraria, speaking honoraria and/or grants from Abbvie, BMS, Celgene Corporation, Dermira, Eli Lilly and Company, Incyte Corporation, Janssen Biotech, Janssen-Ortho, LEO Pharma, US, Lilly ICOS LLC, Novartis, Sun Pharmaceuticals and UCB. AM has received grant support and lecture fees from AbbVie, Esai, Kyowa Hakko Kirin, Leo Pharma, Maruho, Mitsubishi Tanabe Pharma, Novartis and Torii Pharmaceutical and lecture fees from Celgene, Eli Lilly Japan and Janssen Pharmaceutical. JFM has received consulting fees, speaking fees and/or honoraria from AbbVie, Eli Lilly, Novartis, Pfizer, UCB, Celgene, Sanofi, Regeneron, Merck, Biogen Idec and Janssen, and has served as a paid consultant for investment analysis companies Cowen Group and GLG. CYL, JB and MMH are full-time employees and shareholders of Eli Lilly and Company. CLS is a former employee and shareholder of Eli Lilly and Company. DT has been a consultant and advisor and has received speaking fees and grants, and served as an investigator in clinical trials for the following companies: AbbVie, Almirall, Amgen, Biogen Idec, BMS, Boehringer Ingelheim, Celgene, Dignity, Dermavant, Eli Lilly, Galapagos, GSK, Galderma, LEO Pharma, Janssen-Cilag, MSD, Novartis, Pfizer and Regeneron. EDAT- 2019/05/23 06:00 MHDA- 2020/04/01 06:00 PMCR- 2019/10/11 CRDT- 2019/05/23 06:00 PHST- 2018/12/31 00:00 [received] PHST- 2019/04/30 00:00 [revised] PHST- 2019/05/02 00:00 [accepted] PHST- 2019/05/23 06:00 [pubmed] PHST- 2020/04/01 06:00 [medline] PHST- 2019/05/23 06:00 [entrez] PHST- 2019/10/11 00:00 [pmc-release] AID - annrheumdis-2018-215003 [pii] AID - 10.1136/annrheumdis-2018-215003 [doi] PST - ppublish SO - Ann Rheum Dis. 2019 Sep;78(9):1215-1219. doi: 10.1136/annrheumdis-2018-215003. Epub 2019 May 21.